metreleptin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
metreleptin: clinical details
Prescribing considerations
- Confirm the lipodystrophy subtype and licensed eligibility; evidence does not support HIV-related lipodystrophy.
- Review diabetes and lipid-lowering treatment because metabolic improvement may alter requirements.
- Avoid abrupt withdrawal in patients at risk of hypertriglyceridaemia-associated pancreatitis; plan discontinuation with triglyceride monitoring and dietary support.
- Consider individual benefit and risk in previous lymphoma, haematological abnormalities, autoimmune disease, pancreatitis, serious infection, renal impairment or hepatic impairment.
- Review preparation and self-injection technique periodically to reduce medication errors and intramuscular injection.
Contraindications and cautions
- Hypersensitivity to metreleptin or any excipient.
Monitoring
- Weight, appetite and excessive weight loss, particularly in children
- Glucose control and hypoglycaemia when diabetes medicines are used
- HbA1c, triglycerides and other relevant metabolic outcomes
- Signs of pancreatitis, serious infection, hypersensitivity, lymphoma or autoimmune flare
- Clinical response and correct reconstitution and injection technique
- Effect or concentration of narrow-therapeutic-index CYP substrates when metreleptin is started or stopped
Clinical pharmacology
Metreleptin is recombinant methionyl-human leptin. It activates the human leptin receptor through JAK–STAT signalling. Pharmacokinetic data in lipodystrophy are limited; non-clinical evidence indicates renal clearance is the main elimination route, with no formal metabolism studies available.
Formulation and product differences
- The selected product is a 3 mg vial containing white powder for subcutaneous injection after reconstitution. The resulting solution is for immediate, single use and must not be stored.
metreleptin preparations and strengths
Injection
Route: Parenteral
Strengths: 3 mg, 5.8 mg, 11.3 mg
metreleptin interactions
Human interaction studies are limited. Important potential interactions include:
Insulin and insulin secretagogues
Improved insulin sensitivity can increase hypoglycaemia risk, requiring close glucose monitoring and review of diabetes treatment.
Hormonal contraceptives
Contraceptive effectiveness may be reduced; an additional non-hormonal method should be considered.
Warfarin and similar narrow-therapeutic-index medicines
Metreleptin may alter CYP-mediated exposure, so treatment effect should be monitored when metreleptin is started or stopped.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.